Preparation method of catalyst for synthesis of moxifloxacin

The technology of catalyst and auxiliary agent is applied in the field of preparation of catalyst for moxifloxacin synthesis, which can solve the problems of high price, restricting production cost and the like, and achieve the effects of improving stability, strong binding ability and high stability.

Active Publication Date: 2020-01-17
XIAN CATALYST NEW MATERIALS CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Palladium carbon catalyst is a kind of excellent hydrogenation and hydrogenolysis catalyst, is widely used in drug synthesis process, and it has advantages such as small consumption and environmental protection, but its price is expensive, restricts the production cost of moxifloxacin drug to a large extent, therefore Good catalyst activity, selectivity and mechanical performance are the key to the production cost of moxifloxacin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of catalyst for synthesis of moxifloxacin
  • Preparation method of catalyst for synthesis of moxifloxacin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The moxifloxacin synthesis catalyst of the present embodiment comprises activated carbon carrier, the oxide compound of the auxiliary agent element loaded on the activated carbon, and the active component Pd supported on the activated carbon; the auxiliary agent element is Si, the mass of the auxiliary agent element Be 1% of activated carbon mass, the mass percentage composition of active component Pd in ​​the catalyst is 5%;

[0025] The preparation method of described catalyst comprises the following steps:

[0026] Step 1. Weigh the specific surface area to be 820m 2 / g, 30g of activated carbon with a particle size of 200 to 400 meshes, place the weighed activated carbon in a hydrogen peroxide solution with a mass concentration of 5%, stir for 4 hours at 15°C, and wash the retentate with deionized water after filtration until neutral , to obtain activated carbon carrier after drying;

[0027] Step 2: Dissolve 3.04g sodium silicate nonahydrate in deionized water, th...

Embodiment 2

[0030] The moxifloxacin synthesis catalyst of the present embodiment comprises activated carbon carrier, the oxide compound of the auxiliary agent element loaded on the activated carbon, and the active component Pd supported on the activated carbon; the auxiliary agent element is Al, the mass of the auxiliary agent element Be 2% of activated carbon quality, the mass percentage composition of active component Pd in ​​the catalyst is 5%;

[0031] The preparation method of described catalyst comprises the following steps:

[0032] Step 1. Weigh the specific surface area to be 989m 2 / g, 30g of activated carbon with a particle size of 200 to 400 meshes, place the weighed activated carbon in a hydrogen peroxide solution with a mass concentration of 10%, stir at 30°C for 2 hours, and wash the retentate with deionized water after filtration until neutral , to obtain activated carbon carrier after drying;

[0033] Step 2: Dissolve 8.34g aluminum nitrate nonahydrate in deionized wate...

Embodiment 3

[0036] The moxifloxacin synthesis catalyst of the present embodiment comprises activated carbon carrier, the oxide compound of the auxiliary agent element loaded on the activated carbon, and the active component Pd supported on the activated carbon; the auxiliary agent element is Zr, and the mass of the auxiliary agent element Be 3% of activated carbon mass, the mass percentage composition of active component Pd in ​​the catalyst is 5%;

[0037] The preparation method of described catalyst comprises the following steps:

[0038] Step 1. Weigh the specific surface area to be 1463m 2 / g, 30g of activated carbon with a particle size of 200 to 400 meshes, place the weighed activated carbon in an aqueous solution of hydrogen peroxide with a mass concentration of 8%, stir for 3 hours at 25°C, and wash the retentate with deionized water after filtration until neutral , to obtain activated carbon carrier after drying;

[0039] Step 2: Dissolve 4.25g zirconium nitrate pentahydrate in d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
specific surface areaaaaaaaaaaa
specific surface areaaaaaaaaaaa
Login to view more

Abstract

The invention discloses a preparation method of a catalyst for synthesis of moxifloxacin. The catalyst comprises activated carbon, oxide of an aid element loaded on the activated carbon as well as anactive component Pd loaded on the activated carbon; the aid element is Si, Al or Zr. The preparation method of the catalyst comprises the following steps: 1, preparing an activated carbon carrier; 2,modifying the activated carbon carrier by oxide; and 3, dipping and adsorbing an active component palladium to prepare the catalyst. The surface acid-base property of the catalyst is changed and the nitrogen toxicity resistance of the catalyst is enhanced by preferentially adsorbing the aid element oxide on the activated carbon; meanwhile, the active component palladium and the aid element oxide have strong combining capacity, so property reduction of the catalyst caused by loss of the active component metal is avoided; and an glycol aqueous solution serves as a dipping solvent, so that the distribution depth of the active component on the carrier is easier to control, protein type distribution with toxicity resistance is formed and the stability of the catalyst is improved.

Description

technical field [0001] The invention belongs to the technical field of preparation of noble metal catalysts, in particular to a method for preparing a moxifloxacin synthesis catalyst. Background technique [0002] Moxifloxacin, the chemical name is 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]-nonan-8-yl]-6-fluoro-8- Methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid is a fourth-generation broad-spectrum fluoroquinolone antibacterial drug developed by Bayer AG of Germany and launched in Germany in 1999. It is clinically used For the treatment of chronic obstructive pulmonary disease, acute bacterial sinusitis, and skin and soft tissue infections, the drug has strong antibacterial activity, broad antibacterial spectrum, and is not prone to drug resistance. In 2002, it entered the top ten best-selling antibiotic drugs in the world. In the second half of 2002, moxifloxacin was listed in my country. In 2004, the drug entered the national medical insurance catalog, and the m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): B01J23/44C07D471/04
CPCB01J23/44C07D471/04
Inventor 王昭文翟康张磊李岳锋闫江梅万克柔曾永康张之翔
Owner XIAN CATALYST NEW MATERIALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap